Catherine Alix-Panabières: From Discovery to Diagnosis – A Perspective for Circulating Tumor Cells in Personalized Oncology
Catherine Alix-Panabières, Director of the Human Rare Circulating Cells Laboratory (LCCRH) and University Professor at the University Hospital of Montpellier, shared a post on LinkedIn:
“Ever heard of the “Dynamics of liquid biopsy”?
Check out our new review: “From Discovery to Diagnosis: A Perspective for Circulating Tumor Cells in Personalized Oncology” in Cancer Discovery (AACR Journals) – by Catherine Alix-Panabières and Klaus Pantel.
Circulating tumor cells (CTCs) are tumor cells that enter the bloodstream, offering a noninvasive window into cancer biology.
Unlike ctDNA, CTCs reveal protein and RNA expression, helping identify targetable markers and therapy resistance mechanisms.
Tracking CTCs over time shows tumor adaptations in real time, guiding personalized treatment strategies.
Why it matters: Counting and characterizing CTCs provides insights into metastasis, tumor evolution, and therapy response, enabling precision oncology for every patient.”
Title: From Discovery to Diagnosis: A Perspective for Circulating Tumor Cells in Personalized Oncology
Authors: Catherine Alix-Panabières, Klaus Pantel
Read the Full Article.
More posts featuring Catherine Alix-Panabières.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023